CTNM

Contineum Therapeutics

• TipRanks·09/30 16:45

  Jones sees greater room for Contineum’s PIPE-791 to differentiate

• TipRanks·09/30 14:15

  Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·09/30 14:15

  Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from JonesTrading

• Benzinga·09/30 13:55

  Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday

• TipRanks·09/29 20:25

  Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial

• TipRanks·09/29 20:00

  Contineum Therapeutics Inc trading resumes

• TipRanks·09/29 19:55

  Contineum Therapeutics Inc trading halted, volatility trading pause

• TipRanks·09/27 22:50

  Contineum price target lowered to $17 from $18 at Morgan Stanley

• TipRanks·09/27 21:55

  Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading

• TipRanks·09/24 16:20

  Contineum participates in a conference call with William Blair

• TipRanks·09/24 08:50

  Contineum resumed at Early-Stage Biotech at Goldman Sachs

• TipRanks·09/22 01:45

  RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·09/21 14:40

  Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)

• TipRanks·09/19 14:40

  Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)

• NASDAQ·09/18 14:44

  Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead